JMP Securities Reiterates Market Outperform on Rallybio, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated his 'Market Outperform' rating on Rallybio (NASDAQ:RLYB) and maintained a price target of $16.
September 05, 2023 | 11:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its 'Market Outperform' rating on Rallybio and maintained a price target of $16.
The reiteration of the 'Market Outperform' rating and the maintenance of the $16 price target by JMP Securities indicates a positive outlook for Rallybio. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100